Ingredion seals Tate & Lyle takeover, uniting specialty suppliers with personal care reach
Key takeaways
- Ingredion has agreed to a recommended all-cash acquisition of Tate & Lyle.
- The deal unites two suppliers whose specialty platforms extend into personal care formulation.
- Completion is targeted for the second half of 2027, subject to shareholder, UK High Court, and antitrust approvals.
Ingredion has announced a recommended all-cash offer to acquire Tate & Lyle, valuing the target’s share capital at roughly £2.7 billion (US$3.6 billion) and implying an enterprise value of approximately £3.7 billion (US$5 billion). Tate & Lyle’s board has unanimously recommended the offer to shareholders.
The transaction brings together two suppliers whose specialty ingredient portfolios — spanning texturants, hydrocolloids, starches, and nature-derived formulation systems — reach beyond their core food and beverage business and into cosmetics and personal care.
Personal Care Insights reported that when the talks were first confirmed in May, the combination unites overlapping portfolios in specialty ingredients, a category of growing relevance to beauty and personal care manufacturers seeking multifunctional and bio-derived materials.
Broader specialty toolkit for formulators
Both companies have pushed specialty ingredient technologies toward personal care in recent years, as formulators increasingly look for clean label, multifunctional, and naturally-derived alternatives to synthetics.
Tate & Lyle has gradually shifted away from its commodity sugar roots, building out texture systems, clean ingredient solutions, and nature-derived formulation technologies with applications relevant to the personal care sector.
Earlier this year, the company joined a Personal Care Insights webinar on naturally-derived alternatives to synthetic skin care thickeners, where it highlighted its move into clean label beauty formulation technologies.
Ingredion has agreed to a recommended all-cash takeover of Tate & Lyle.
Much of that reach came from Tate & Lyle’s US$1.8 billion acquisition of CP Kelco, completed in November 2024. The deal strengthened Tate & Lyle’s capabilities in pectin and specialty gums and gave it access to fermentation-derived ingredients sourced from citrus peel and seaweed — materials increasingly explored in beauty product development.
While Ingredion frames CP Kelco’s contribution around mouthfeel and texture, the underlying hydrocolloid and biopolymer technologies belong to the same families of materials used across cosmetic and personal care applications.
Ingredion, while primarily active in starches, sweeteners, and nutrition ingredients, also supplies biomaterials and starch-based technologies used in personal care formulations, including texture modifiers and naturally-derived alternatives to synthetic ingredients. The combined group’s enlarged texturant and nature-derived portfolio could give personal care formulators a broader single-supplier menu of thickening, texturizing, and clean label systems.
Neither company has explicitly announced any personal care-specific strategy tied to the transaction. The official rationale centers on the companies’ F&B business, and the stated synergy and growth case is built around texture, sugar reduction, mouthfeel, sweetening, and fortification.
Any personal care upside flows from the overlap in specialty ingredient technologies rather than from a declared beauty pivot. But for cosmetic chemists, the practical outcome is a larger combined supplier spanning many of the texturizing and nature-derived material families used in formulation.
Other companies operating across F&B and cosmetics have shaved off business arms to focus on beauty. Earlier this year, Unilever offloaded its Foods business to focus on its home and personal care sectors.
Deal terms
Under the terms, Tate & Lyle shareholders will receive 595 pence per share, an approximate 59% premium to the company’s closing price on May 13, 2026, plus permitted final and interim dividends. Ingredion chairman, president, and CEO Jim Zallie said combining the two companies’ complementary portfolios establishes a global leader in ingredient solutions with the innovation expertise and geographic reach to serve evolving customer demand. 
Both companies supply specialty ingredients used in personal care formulations.
The combined group would draw on complementary supply networks across the Americas, Europe, the Middle East and Africa, and the Asia Pacific. Ingredion expects run-rate net cost synergies of approximately US$130 million fully realized by the end of 2030, against one-time costs of about US$175 million, with the deal expected to be accretive to adjusted earnings per share in the first year after completion.
The acquisition is expected to be implemented through a court-sanctioned scheme of arrangement under the UK Companies Act 2006, though Ingredion reserves the right to proceed by takeover offer. Completion remains subject to Tate & Lyle shareholder approval, UK High Court sanction, and antitrust clearances. Ingredion has received an irrevocable undertaking from Huber Equity Corporation covering approximately 16.8% of Tate & Lyle’s issued ordinary share capital. The transaction is expected to be completed in the second half of 2027.
